AstraZeneca Pharmaceuticals LP
NEWS
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
The National Institutes of Health is raising concern about the safety of AstraZeneca’s coronavirus vaccine, even as the U.S. FDA is weighing whether or not to resume testing in the United States following a global pause in the trial for safety reasons.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
It was a busy week for clinical trial updates. Here’s a look.
Despite a temporary pause on its COVID-19 vaccine trial, AstraZeneca Chief Executive Officer Pascal Soriot said the preventative drug could still be available for commercial use by the end of the year, or in early 2021 barring any other setback.
JOBS
IN THE PRESS